Appointment of Chief Financial Officer

Quantum Pharma Plc

("Quantum", the "Company" or the "Group")

Appointment of Chief Financial Officer

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that Chris Rigg has been promoted today to the role of Chief Financial Officer, and to Quantum's Board. His appointment follows the resignation of Martin Such, the Group's Chief Financial Officer on 7 March 2016.

Chris joined Quantum as the Group's Strategic Director in November 2015, since which time he has been working as part of the senior management team reporting to the Board on a broad range of Group matters.

Chris qualified as a chartered accountant at PwC and then moved to corporate finance at Deloitte for eight years. In 2009, he joined Eaga plc first as group corporate finance director and subsequently as divisional managing director of the solar division. After Eaga's acquisition by Carillion Plc in 2011, Chris joined Barclays to head its North East large corporate banking division. Two years later, Chris became CEO of NRG, a national recruitment agency, where he worked until joining Quantum.

Commenting on the appointment, Andrew Scaife, Chief Executive Officer of Quantum, said: "We are delighted to welcome Chris to the Board as Chief Financial Officer. Chris has a wealth of relevant experience in management, finance and strategic matters and, having joined the Group last November, a good understanding of the Group's businesses.

"On behalf of the Board I would like to extend sincere thanks to Martin Such for his significant contribution to the success and growth of the Company during the past eight years and, in particular, to its listing in 2014. We wish him every success going forward."

Final Results Date

The Board confirms that the Group's expectations remain as set out in the Trading Update issued on 19 January 2016 with adjusted Group EBITDA for the year ended 31 January 2016 expected to be around £12.7 million. The Company will be announcing its Final Results on Tuesday, 10 May 2016. An analyst briefing will be held at 09.30hrs at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Christian Alexander Rigg, age 41 years, has been a director of the following companies during the five years preceding the date of this announcement:

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials

Comprising four business units:

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch-made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development as well as clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared, sterile intravenous products, either individually, for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Niche Pharmaceuticals

Comprising three business units:

Colonis® is a product development business, which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full-service contract development specialist with customers across Europe. It specialises in creating added-value products with distinct advantages for patients and health care providers. It also provides full services for the entire development chain - from inception to registration to post-approval, finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

Medication Adherence

Comprising two business units:

Biodose® is a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. Biodose Connect® - a telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.